Gemtuzumab ozogamicin (GO) is a calicheamicin-conjugated antibody directed against CD33, an antigen highly expressed on acute myeloid leukemic (AML) cells. CD33-specific binding triggers internalization of GO and subsequent hydrolytic release of calicheamicin. Calicheamicin then translocates to the nucleus, intercalates in the DNA structure and subsequently induces double-strand DNA breaks. GO is part of clinical practice for AML, but is frequently associated with severe side effects. Therefore, combination of GO with other therapeutics is warranted to reduce toxicity, while maximizing therapeutic selectivity. We hypothesized that the histone deacetylase inhibitor valproic acid (VPA) sensitizes AML cells to GO. VPAinduced histone hyperacetylation opens the chromatin structure, whereby the DNA intercalation of calicheamicin should be augmented. We found that clinically relevant concentrations of VPA potently augmented the tumoricidal activity of GO towards AML cell lines and primary AML blasts. Moreover, VPA treatment indeed augmented the DNA intercalation of calicheamicin and enhanced DNA degradation. Importantly, synergy was restricted to CD33-positive AML cells and did not require caspase activation. In conclusion, the synergistic proapoptotic activity of cotreatment of AML cells with VPA and GO indicates the potential value of this strategy for AML.
Introduction
The immunotoxin gemtuzumab ozogamicin (GO; Mylotarg) comprises a powerful tumoricidal calicheamicin derivative chemically linked to an antibody that specifically targets the internalizing transmembrane protein CD33.
1 CD33 is highly expressed on leukemic blasts of a majority of acute myeloid leukemia (AML) patients, 2 whereas CD33 is not expressed on normal hematopoietic stem cells nor on non-hematopoietic cells. 3 These characteristics have led to the development of GO and other CD33-targeted immunotoxins. 4 Importantly, expression of CD33 has also been reported on leukemic stem cells, 5 further establishing CD33 as a promising target antigen in AML.
Binding of GO to CD33 leads to internalization and subsequent dissociation of the calicheamicin derivative in the lysosome, whereupon the toxin translocates to the nucleus. In the nucleus, calicheamicin binds in the minor groove of the DNA double-helix and induces sequence-specific double-strand breaks, 6 ultimately resulting in apoptosis. GO is approved for relapsed AML (X60 years) and for patients for whom conventional chemotherapy is contraindicated. 7 GO has a generally acceptable safety profile, 8 but nevertheless is associated with severe toxicity in some patients, including hepatotoxicity 9 and severe myelosuppression. 10 Therefore, the rational design of combinatorial approaches of GO with other therapeutics is warranted in order to achieve optimal tumoricidal activity with reduced toxicity. A promising candidate for such a combinatorial approach is valproic acid (VPA), which in recent phase II clinical trials showed promising single agent activity towards AML.
11
VPA has been part of clinical practice for many years as an anticonvulsant. 12 More recently, VPA was reported to be a histone deacetylase inhibitor that shows promising tumoricidal activity. 13, 14 Treatment with VPA induces a hyper-acetylated state of histones, 15 resulting in a more open chromatin structure. Consequently, the DNA becomes more accessible to intercalating agents 15 and transcription of a limited set of genes is altered, 16 rendering cells more prone to apoptosis. Therefore, we hypothesized that treatment of AML cells with VPA should augment calicheamicin binding capacity and potentiate the apoptotic activity of GO.
Materials and methods

Chemicals and reagents
Gemtuzumab ozogamicin (Wyeth-Ayerst Laboratories, St Davids, PA, USA) was dissolved at a stock concentration of 1 mg/ ml in dH 2 O and stored at À801C. The histone deacetylase inhibitor VPA (Sigma Aldrich, Zwijndrecht, The Netherlands) was dissolved at a stock concentration of 100 mM in dH 2 O, and stored at À201C. The pan-caspase inhibitor Z-VAD-FMK (Calbiochem, San Diego, CA, USA) was dissolved at 10 mM in dimethylsulfoxide and stored at À201C.
Cell culture
The CD33-positive AML cell lines U-937 17 and THP-1 and the CD33-negative B-cell line Ramos were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were cultured in RPMI (Cambrex, East Rutherford, NJ, USA) supplemented with 10% fetal calf serum at 371C in a humidified 5% CO 2 atmosphere under standard conditions. For all experiments, cells were seeded at 2.5 Â 10 6 cells/well in a six-well plate.
Apoptosis assays
Apoptosis was assessed by: Phoshatidylserine exposure (PS): PS exposure was analyzed by flow cytometry using the Annexin V-FITC/PI kit (NeXins Research, Kattendijke, The Netherlands) according to manufacturer's protocol. Loss of mitochondrial -membrane potential (Dc): Dc was analyzed using the cellpermeant green-fluorescent lipophilic dye DiOC6 (Molecular Probes, Eugene, OR, USA). After treatment, cells were harvested by centrifugation (300 g for 5 min), incubated for 20 min at 371C with 0.1 mM DiOC6 in fresh medium, washed once with phosphate-buffered saline (PBS) and analyzed by flow cytometry. Caspase-3 processing by immunoblot: cell lysates were prepared essentially as described previously. 18 30 mg of lysate was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (12.5% AA) under reducing conditions and transferred to nitrocellulose (Bio-Rad, Veenendaal, The Netherlands) by electroblotting. Blots were incubated with a primary polyclonal antibody, directed at the N-terminus of caspase-3, followed by an appropriate secondary HRPO-conjugated antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Specific binding was visualized by chemoluminescence (Roche Diagnostics, Almere, The Netherlands). Incubations were performed for 1.5 h in PBS, 5% skim milk and were followed by three washes with PBS containing 0.1% Tween-20. Caspase-3/7 activity: briefly, 1.0 Â 10 5 cells were plated per well in a 96-well plate and incubated for 24 h with or without VPA and GO. Activation of caspase-3/-7 was assessed by the caspase-Glot3/7 assay kit (Promega, Mannheim, Germany) according to manufacturer's protocol.
Synergy was quantified using the cooperativity index (CI ¼ sum of apoptosis of single agent treatment/apoptosis upon combined treatment). CIo1 was termed synergistic, CI ¼ 1 was termed additive and CI41 was termed antagonistic. Statistical analysis was performed using the two-tailed Student's t-test.
Assessment of DNA-intercalation by calicheamicin
The effect of VPA on the DNA-intercalation of calicheamicin was assessed by fluorescence microscopy using intact GO. Staining against the IgG4 Fc-domain of intact GO provides a convenient and rapid method to indirectly determine DNA intercalation of the calicheamicin moiety. CD33-negative Ramos cells were incubated for 24 h in the absence or presence of VPA (1 mM), spotted on microscope slides and permeabilized with acetone. Subsequently, cells were incubated with 100 ml PBS containing 250 mg/ml GO (15 min/RT), washed twice and fixed with 4% paraformaldehyde. Specific binding was analyzed using anti-human IgG-biotin followed by Cy3-conjugated streptavidin (DAKO Cytomation, Glostrup, Denmark). 4,6-Diamidino-2-phenylindole (DAPI) was used to stain nuclei. Staining was evaluated using a Quantimed-600S fluorescence microscope (Leica Camera, Solms, Germany).
Assessment of DNA degradation by GO
U-937 cells were incubated for 24 h in the absence or presence of VPA (1 mM). Subsequently, DNA was isolated using the DNA-easy isolation kit (Qiagen, Venlo, The Netherlands). Isolated DNA (3 mg) was treated with GO (400 mg/ml) in the presence of the reducing agent dithiothreitol (5 mM) for 18 h at 371C and subsequently analyzed for fragmentation on an 0.8% agarose gel.
Synergistic apoptosis induction by GO and VPA in patient-derived CD33-positive AML. Isolated patientderived AML cells, containing over 50% blasts, were treated for 24 h with GO, VPA and a combination of GO and VPA at the indicated concentrations. Subsequently, apoptosis was assessed by determination of PS exposure. Percentage of specific apoptosis was calculated using the following formula: specific apoptosis ¼ (experimental apoptosisÀspontaneous apoptosis)/ (100Àspontaneous apoptosis) Â 100%.
Results and discussion
Despite the generally acceptable safety profile of GO, 8 treatment is still associated with severe toxicity in some patients. In order to reduce the severity or prevalence of toxicity, the rational design of combinatorial strategies with other therapeutics that augment the tumoricidal activity of GO is warranted. Hereby, the minimally required dose of GO can be reduced, while maximizing therapeutic selectivity. To test our hypothesis that the histone deacetylase inhibitor VPA is a promising candidate for combination with GO, CD33-positive and CD33-negative cell lines were co-treated with VPA and GO. In the CD33-positive AML cell lines U-937 and THP-1, co-treatment with VPA and GO synergistically activated apoptosis (Figure 1a , CI of 0.45 and 0.87, respectively). Moreover, synergistic apoptosis induction by VPA and GO was dose-dependent and significant at all concentrations tested (Figure 1b) . Similar results were obtained when cells were co-treated with GO and the histone deacetylase inhibitors sodium butyrate (NaBu) and trichostatin A (TSA) (data not shown), further confirming our hypothesis that histone deacetylase inhibition augments GO-induced apoptosis in CD33-positive cells. In contrast, co-treatment of CD33-negative Ramos cells with VPA and GO did not significantly induce apoptosis and was even antagonistic (Figure 1a , CI of 1.9), indicating that the synergistic effect of GO and VPA critically depends on the CD33-specific binding and subsequent processing of GO.
Intriguingly, time course experiments revealed a synchronized induction of apoptosis within 20-24 h of treatment with VPA and GO (Figure 1c) , a finding suggestive of an underlying cell cycle arrest. However, no differences in cell cycle status were found between single-agent treatment and co-treatment (data not shown), thus excluding a prominent role for cell cycle arrest.
Apoptosis upon co-treatment with VPA and GO was characterized by processing and activation of caspase-3 ( Figure 1d ). However, AML cells subjected to co-treatment in the presence of a pan-caspase inhibitor were still eliminated by apoptosis (Figure 1e) , which indicates that caspase activity is dispensable for the execution of apoptosis.
Importantly, the synergistic proapoptotic effect on AML cell lines was detected at concentrations of VPA and GO realistically attainable in patient plasma. 19 Moreover, similar experiments on primary AML blasts demonstrated that these cells are even more susceptible to apoptosis induction by VPA and GO cotreatment (Figure 1f , CI of 0.75).
Recently, Marchion et al. 15 demonstrated that VPA increases the accessibility of DNA to intercalating agents, such as the topoisomerase ll inhibitor epirubicin. To assess whether VPA similarly increased the accessibility of DNA for the calicheamicin moiety of GO, we analyzed the intercalation of calicheamicin on permeabilized CD33-negative Ramos cells by fluorescence microscopy (Figure 2a) . Intact GO was used to indirectly assess DNA-intercalation of calicheamicin in the minor groove by staining against the IgG4 Fc-domain of GO. Compared to non-treated Ramos cells (Figure 2a, panel 2) , a marked increase in staining intensity was detected in VPAtreated cells, especially in the nucleus (Figure 2a, panel 3) , indicating that VPA augments the intercalation of calicheamicin. These results were confirmed using the histone deacetylase inhibitors NaBu and TSA, resulting in a similar increase in GO intercalation (data not shown). Importantly, DNA degradation by calicheamicin was also strongly enhanced in DNA isolated from VPA-treated U-937 cells (Figure 2b) . Together, these data demonstrate that histone deacetylase inhibitors, of which VPA is of particular interest for AML, enhance CD33-restricted apoptosis induction by increasing the DNA-intercalation of calicheamicin. This results in enhanced DNA-degradation and concomitant potent apoptosis induction.
In addition, although not investigated here, the respective down-or upregulation of anti-or proapoptotic proteins by VPA may be involved in the observed synergistic proapoptotic effect.
In conclusion, the design of novel combinatorial treatment strategies of GO with other therapeutics is warranted in order to achieve high tumoricidal activity with potentially reduced or non-overlapping toxicity. In this respect, GO has already been (c) U-937 cells were subjected to single-agent treatment or co-treatment with GO (2.5 mg/ml) and VPA (1 mM). At various time points, apoptosis was assessed by determination of PS exposure. (d) U-937 cells were subjected to single agent and co-treatment with GO (2.5 mg/ml) and VPA (1 mM) for 24 h, after which caspase-3/-7 activity was assessed as described in Methods. Analysis of pro-caspase 3 processing was performed by immunoblotting. (e) U-937 cells were subjected to single-agent treatment or co-treatment with GO (2.5 mg/ml) and VPA (1 mM) in the presence or absence of the pan-caspase inhibitor Z-VAD-FMK (20 mM). Apoptosis was assessed by determination of PS exposure. Indicated values are means7s.e.m. of three independent experiments. (f) Primary AML blasts (n ¼ 2) were subjected to single-agent treatment and co-treatment with VPA (0.5 mM) and GO (2.5 mg/ml). Apoptosis was assessed by determination of PS exposure. Indicated values are means7s.d.
VPA augments the apoptotic activity of GO in AML B ten Cate et al combined with standard chemotherapeutics in clinical trials. 20 Here, we describe the strong synergistic proapoptotic effect of co-treatment of AML cells with the histone deacetylase inhibitor VPA and GO. Synergy is restricted to CD33-positive cells and can occur caspase-independent, which might help to overcome chemotherapy resistance related to defects in caspase activation pathways. 21 Taken together, further pre-clinical exploration of this combinatorial strategy appears warranted to determine its potential clinical feasibility for AML. U-937 cells were treated for 24 h with/without VPA (1 mM), after which DNA was isolated. Isolated DNA was subjected to GO (400 mg/ml), after which DNA-degradation was assessed as described in Materials and methods. DNA-degradation was visualized on agarose gel.
